Latest From DeuteRx LLC
Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.
- Therapeutic Areas
- Hepatic (Liver)
- North America
- Parent & Subsidiaries
- DeuteRx LLC
- Senior Management
Sheila DeWitt, PhD, Pres. & CEO
Vincent Jacques, PhD, VP, Research & Early Dev.
- Contact Info
Phone: (978) 662-5287
300 Brickstone Sq.
Andover, MA 01810
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.